S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
Log in
NASDAQ:FGEN

FibroGen Competitors

$48.99
-0.60 (-1.21 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$48.41
Now: $48.99
$50.64
50-Day Range
$37.09
MA: $41.24
$49.59
52-Week Range
$22.65
Now: $48.99
$51.56
Volume961,699 shs
Average Volume720,512 shs
Market Capitalization$4.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.59

Competitors

FibroGen (NASDAQ:FGEN) Vs. CVAC, HZNP, BMRN, ELAN, TEVA, and GRFS

Should you be buying FGEN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to FibroGen, including CureVac (CVAC), Horizon Therapeutics Public (HZNP), BioMarin Pharmaceutical (BMRN), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), and Grifols (GRFS).

FibroGen (NASDAQ:FGEN) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and CureVac, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FibroGen12302.33
CureVac11202.25

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. CureVac has a consensus target price of $58.3333, suggesting a potential downside of 40.92%. Given FibroGen's stronger consensus rating and higher probable upside, equities analysts plainly believe FibroGen is more favorable than CureVac.

Profitability

This table compares FibroGen and CureVac's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FibroGen-191.78%-48.19%-27.72%
CureVacN/AN/AN/A

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 4.3% of CureVac shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares FibroGen and CureVac's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroGen$256.58 million17.38$-76,970,000.00($0.89)-55.04
CureVacN/AN/AN/AN/AN/A

CureVac has lower revenue, but higher earnings than FibroGen.

Summary

FibroGen beats CureVac on 6 of the 9 factors compared between the two stocks.

FibroGen (NASDAQ:FGEN) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and Horizon Therapeutics Public, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FibroGen12302.33
Horizon Therapeutics Public00803.00

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. Horizon Therapeutics Public has a consensus target price of $93.6667, suggesting a potential upside of 24.94%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, analysts plainly believe Horizon Therapeutics Public is more favorable than FibroGen.

Profitability

This table compares FibroGen and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FibroGen-191.78%-48.19%-27.72%
Horizon Therapeutics Public43.55%25.66%14.19%

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

FibroGen has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.

Valuation & Earnings

This table compares FibroGen and Horizon Therapeutics Public's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroGen$256.58 million17.38$-76,970,000.00($0.89)-55.04
Horizon Therapeutics Public$1.30 billion12.73$573.02 million$1.9438.64

Horizon Therapeutics Public has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Summary

Horizon Therapeutics Public beats FibroGen on 12 of the 14 factors compared between the two stocks.

FibroGen (NASDAQ:FGEN) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and BioMarin Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FibroGen12302.33
BioMarin Pharmaceutical091102.55

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. BioMarin Pharmaceutical has a consensus target price of $116.50, suggesting a potential upside of 35.61%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than FibroGen.

Profitability

This table compares FibroGen and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FibroGen-191.78%-48.19%-27.72%
BioMarin Pharmaceutical45.74%4.34%2.84%

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 97.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

FibroGen has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Valuation & Earnings

This table compares FibroGen and BioMarin Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroGen$256.58 million17.38$-76,970,000.00($0.89)-55.04
BioMarin Pharmaceutical$1.70 billion9.15$-23,850,000.00$0.071,227.29

BioMarin Pharmaceutical has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

BioMarin Pharmaceutical beats FibroGen on 11 of the 14 factors compared between the two stocks.

FibroGen (NASDAQ:FGEN) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and Elanco Animal Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FibroGen12302.33
Elanco Animal Health23502.30

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. Elanco Animal Health has a consensus target price of $29.2778, suggesting a potential downside of 3.53%. Given FibroGen's stronger consensus rating and higher probable upside, equities analysts plainly believe FibroGen is more favorable than Elanco Animal Health.

Profitability

This table compares FibroGen and Elanco Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FibroGen-191.78%-48.19%-27.72%
Elanco Animal Health-8.45%3.43%2.04%

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Comparatively, 0.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

FibroGen has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Valuation & Earnings

This table compares FibroGen and Elanco Animal Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroGen$256.58 million17.38$-76,970,000.00($0.89)-55.04
Elanco Animal Health$3.07 billion4.66$67.90 million$1.0628.63

Elanco Animal Health has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Summary

Elanco Animal Health beats FibroGen on 8 of the 14 factors compared between the two stocks.

FibroGen (NASDAQ:FGEN) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and Teva Pharmaceutical Industries, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FibroGen12302.33
Teva Pharmaceutical Industries310402.06

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. Teva Pharmaceutical Industries has a consensus target price of $12.2857, suggesting a potential downside of 0.28%. Given FibroGen's stronger consensus rating and higher probable upside, equities analysts plainly believe FibroGen is more favorable than Teva Pharmaceutical Industries.

Profitability

This table compares FibroGen and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FibroGen-191.78%-48.19%-27.72%
Teva Pharmaceutical Industries-24.17%19.32%4.89%

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

FibroGen has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.

Valuation & Earnings

This table compares FibroGen and Teva Pharmaceutical Industries' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroGen$256.58 million17.38$-76,970,000.00($0.89)-55.04
Teva Pharmaceutical Industries$16.89 billion0.80$-998,000,000.00$2.315.33

FibroGen has higher earnings, but lower revenue than Teva Pharmaceutical Industries. FibroGen is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

FibroGen (NASDAQ:FGEN) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Risk and Volatility

FibroGen has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Profitability

This table compares FibroGen and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FibroGen-191.78%-48.19%-27.72%
Grifols12.79%10.65%4.79%

Valuation & Earnings

This table compares FibroGen and Grifols' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroGen$256.58 million17.38$-76,970,000.00($0.89)-55.04
Grifols$5.71 billion2.22$700.16 million$1.1715.77

Grifols has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and Grifols, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FibroGen12302.33
Grifols05302.38

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. Given FibroGen's higher probable upside, equities analysts plainly believe FibroGen is more favorable than Grifols.

Summary

Grifols beats FibroGen on 8 of the 13 factors compared between the two stocks.


FibroGen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CureVac logo
CVAC
CureVac
0.6$98.73-5.8%$17.37 billionN/A0.00Analyst Upgrade
Gap Up
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$74.97-4.7%$16.55 billion$1.30 billion20.48
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$85.91-3.6%$15.60 billion$1.70 billion19.66
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$30.35-1.3%$14.32 billion$3.07 billion-53.25News Coverage
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$12.32-0.6%$13.46 billion$16.89 billion-3.35
Grifols logo
GRFS
Grifols
1.2$18.45-2.9%$12.69 billion$5.71 billion16.47
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$68.59-1.1%$11.37 billion$2.32 billion56.69Upcoming Earnings
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.4$203.83-4.5%$10.25 billion$3.34 million-26.47Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.2$170.69-5.1%$9.92 billion$12.98 million-56.33Analyst Downgrade
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$26.45-2.1%$9.39 billion$8.60 billion-4.85Analyst Revision
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$166.05-3.0%$9.25 billion$2.16 billion52.38
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.0$62.52-2.0%$8.74 billion$1.12 billion130.25Insider Selling
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.3$139.97-4.9%$8.54 billion$103.71 million-31.88Analyst Report
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$81.14-3.7%$8.34 billion$87.99 million-96.60
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$155.72-2.0%$8.32 billion$14.98 million-18.97High Trading Volume
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.6$51.61-4.5%$8.20 billion$339.08 million-30.01
BBIO
BridgeBio Pharma
1.6$62.33-5.6%$7.65 billion$40.56 million-18.28High Trading Volume
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.3$164.85-2.7%$7.33 billion$1.45 billion15.60Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$92.65-3.7%$7.31 billion$380.83 million-11.85
Galapagos logo
GLPG
Galapagos
1.3$111.28-0.0%$7.28 billion$1.00 billion-16.86
Allakos logo
ALLK
Allakos
1.2$127.89-2.8%$6.71 billionN/A-46.68
TG Therapeutics logo
TGTX
TG Therapeutics
1.4$50.01-0.5%$6.58 billion$150,000.00-23.59
SDGR
Schrödinger
1.3$93.45-2.9%$6.49 billion$85.54 million0.00Analyst Report
TPTX
Turning Point Therapeutics
1.7$128.07-4.7%$6.17 billionN/A-36.49
Perrigo logo
PRGO
Perrigo
2.2$44.49-0.0%$6.07 billion$4.84 billion-741.38
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.6$109.37-2.7%$5.80 billion$1.11 billion35.17
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$96.91-6.2%$5.40 billion$66.51 million17.88
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$31.75-0.6%$5.35 billionN/A0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.4$88.78-2.6%$5.32 billionN/A-7.24
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.4$19.77-3.4%$5.15 billion$182.24 million-17.19
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$122.21-0.0%$4.75 billion$26.69 million-46.12
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.7$150.23-4.6%$4.66 billion$311.33 million-87.34Insider Selling
Analyst Revision
AVIR
Atea Pharmaceuticals
1.7$56.00-1.1%$4.63 billionN/A0.00
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$76.36-2.1%$4.44 billion$806.43 million-10.82
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.2$33.26-2.3%$4.44 billion$204.89 million-41.58
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$83.48-8.4%$4.34 billion$6.87 million-8.07
Insmed logo
INSM
Insmed
1.2$42.25-3.8%$4.30 billion$136.47 million-16.25
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$61.18-3.8%$4.17 billion$306.98 million-8.75
ChemoCentryx logo
CCXI
ChemoCentryx
1.8$59.29-9.3%$4.10 billion$36.13 million-88.49
MorphoSys logo
MOR
MorphoSys
0.4$30.66-2.8%$4.03 billion$80.43 million146.01Gap Down
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$117.01-0.1%$3.99 billion$26.52 million-10.31News Coverage
ARVN
Arvinas
2.0$74.03-11.5%$3.58 billion$42.98 million-28.92
LEGN
Legend Biotech
1.2$27.57-3.2%$3.56 billion$64.39 million0.00
OPKO Health logo
OPK
OPKO Health
1.9$5.26-4.6%$3.52 billion$901.90 million-29.22High Trading Volume
Alkermes logo
ALKS
Alkermes
1.2$21.69-5.4%$3.45 billion$1.17 billion-47.15
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.8$44.89-3.1%$3.40 billionN/A-6.05News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$48.04-3.0%$3.33 billion$117.91 million-9.74
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$28.52-0.1%$3.31 billion$306.49 million32.05
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$18.24-2.7%$3.27 billion$114.62 million-7.35
PRLD
Prelude Therapeutics
1.0$69.93-7.2%$3.06 billionN/A0.00
This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.